Article
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
Gynecologic oncology - 1 May 2012
Rubatt Jennifer M, Darcy Kathleen M, Tian Chunqiao, Muggia Franco, Dhir Rajiv, Armstrong Deborah K, Bookman Michael A, Niedernhofer Laura J, Deloia Julie, Birrer Michael, Krivak Thomas Carl
Abstract excerpt
OBJECTIVE: Excision repair cross-complementation group 1 (ERCC1) is required for the repair of platinum-induced DNA damage. This study sought to assess the prognostic value of ERCC1 expression, measured by immunohistochemistry (IHC) using a highly specific antibody, in advanced epithelial ovarian cancer (EOC) patients treated with platinum-based chemotherapy. METHODS: Formalin-fixed, paraffin-embedded tumors were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.